Literature DB >> 1657084

Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.

R J MacFadyen1, K R Lees, J L Reid.   

Abstract

OBJECTIVE: To compare the first dose responses to low dose angiotensin converting enzyme inhibitors (captopril, enalapril, and perindopril) in elderly patients with stable chronic heart failure.
DESIGN: Double blind, randomised, placebo controlled, parallel, group prospective study of elderly patients with stable chronic heart failure.
SETTING: General hospital in-patient admissions for supervised diuretic withdrawal (24-48 hours) and the introduction of angiotensin converting enzyme inhibitor therapy. PATIENTS: 48 unselected elderly (58-85 years) patients with symptomatic but stable chronic heart failure (New York Heart Association grades II-IV) confirmed by clinical history, examination, and cardiological investigations. Patients gave their written and informed consent to receive their initial treatment under double blind conditions; blood pressure was monitored and blood samples taken to measure the pharmacokinetic and neurohormonal responses. INTERVENTION: Patients were randomised to receive a daily oral dose of placebo, captopril (6.25 mg), enalapril (2.5 mg), or perindopril (2 mg). MAIN OUTCOME MEASURES: Blood pressure and heart rate responses, drug concentration, and plasma renin and ACE activities. Differences between treatment groups were analysed by analysis of variance.
RESULTS: The four randomised groups of patients had similar age, severity of heart failure (NYHA class), pretreatment diuretic dosage, plasma renin activity, and serum electrolyte state. Placebo treatment caused a modest but significant diurnal fall in blood pressure. Captopril produced a significant early (1.5 hours) and brief fall in blood pressure. The blood pressure fall with enalapril was later (4-10 hours), longer lasting, and was associated with significant slowing of supine heart rate. Though perindopril produced a similar plasma ACE inhibition to that produced by enalapril, it only caused changes in blood pressure that were similar to those caused by placebo.
CONCLUSIONS: This controlled study is the first to indicate a qualitative difference in the acute response to angiotensin converting enzyme inhibitors with similar structure and metabolism (that is, enalapril and perindopril). Low dose perindopril seems to be less likely to cause hypotension in patients with heart failure. The explanation for the differences is unclear but may reflect differential effects on local tissue angiotensin generation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657084      PMCID: PMC1024645          DOI: 10.1136/hrt.66.3.206

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  27 in total

1.  A modified ajmaline test for prediction of the effective refractory period of the accessory pathway in the Wolff-Parkinson-White syndrome.

Authors:  M Chimienti; M Moizi; C Klersy; L Guasti; J A Salerno
Journal:  Am J Cardiol       Date:  1987-01-01       Impact factor: 2.778

2.  Intravenous captopril in acute heart failure.

Authors:  K Flynn; M G Coughlan; D M Phelan; D Luke; M Neligan; A E Wood
Journal:  Lancet       Date:  1988-01-23       Impact factor: 79.321

3.  Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure.

Authors:  B Fabris; B Jackson; M Kohzuki; R Perich; C I Johnston
Journal:  Clin Exp Pharmacol Physiol       Date:  1990-04       Impact factor: 2.557

4.  Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses.

Authors:  B M Massie; B L Kramer; N Topic
Journal:  Circulation       Date:  1984-06       Impact factor: 29.690

5.  Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure.

Authors:  M Packer; N Medina; M Yushak
Journal:  Circulation       Date:  1985-04       Impact factor: 29.690

6.  Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure.

Authors:  I S Anand; R Ferrari; G S Kalra; P L Wahi; P A Poole-Wilson; P C Harris
Journal:  Circulation       Date:  1989-08       Impact factor: 29.690

7.  Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations.

Authors:  T R Porter; D L Eckberg; J M Fritsch; R F Rea; L A Beightol; J F Schmedtje; P K Mohanty
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

8.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.

Authors:  J Bayliss; M Norell; R Canepa-Anson; G Sutton; P Poole-Wilson
Journal:  Br Heart J       Date:  1987-01

9.  A survey of current use of angiotensin-converting-enzyme inhibitors by Scottish physicians in the treatment of chronic cardiac failure.

Authors:  J McMurray; C C Lang; D D Maclean; D G McDevitt; A D Struthers
Journal:  Scott Med J       Date:  1989-04       Impact factor: 0.729

10.  Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man.

Authors:  B C Campbell; A Sturani; J L Reid
Journal:  Clin Sci (Lond)       Date:  1985-01       Impact factor: 6.124

View more
  21 in total

1.  Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial.

Authors:  C Bulpitt; A Fletcher; N Beckett; J Coope; B Gil-Extremera; F Forette; C Nachev; J Potter; P Sever; J Staessen; C Swift; J Tuomilehto
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Formulary management of ACE inhibitors.

Authors:  K R Gerbrandt; K C Yedinak
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 4.  Optimal dosage of ACE inhibitors in older patients.

Authors:  B Tomlinson
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

5.  The effect of captopril on the superior mesenteric artery and portal venous blood flow in normal man.

Authors:  K Ray-Chaudhuri; T Thomaides; S Maule; L Watson; S Lowe; C J Mathias
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

6.  Effects of captopril and enalapril on renal function in elderly patients with chronic heart failure.

Authors:  C A Haffner; M J Kendall; A D Struthers; A Bridges; D J Stott
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

7.  Prolonged First-Dose Hypotension Induced by Sacubitril/Valsartan.

Authors:  Fu-Chih Hsiao; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2018-01       Impact factor: 2.672

Review 8.  Perindopril: in congestive heart failure.

Authors:  Dene Simpson; Stuart Noble; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man.

Authors:  R J MacFadyen; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

Review 10.  The new trials: AIRE, ISIS-4, and GISSI-3. Is the dossier on ACE inhibitors and myocardial infarction now complete?

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1994-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.